In June, Eve alongside our CEO, Rick and Administrative Officer, Will attended the REMEDi4ALL General Annual Meeting in Amsterdam.
Eve’s blog summarises the two-day GAM with a focus on ‘patient centricity’ and how Beacon plays a part in ‘teaching the next generation of re-purposers’.
Patient centricity
After setting the scene on the first day, we heard from scientists, regulators, funders, health economists and more over the duration of the meeting and all maintained this key, crucial message in their work and plans. It is extremely encouraging to see people within every stage Genof the drug development pathway thinking about how we get a drug through all the tricky ups and downs of development and approval, to patients directly in the cheapest, easiest, fastest way.
If everyone is aligned on this common goal – this will make collaboration and partnership easier and mean that we really do see patient impact as soon as possible.
Teaching the next generation of re-purposers
It was again really encouraging to hear that all partners in the consortium agree with our training plans, that regulators want to make their language accessible to all and health economists are our greatest allies at times, despite the perceived reputation.
We hope that our role in REMEDi4ALL is to encourage a collaborative approach to education where every stakeholder can communicate to the other about what they want and need to succeed.
Until next time!
Here at Beacon we will be looking at our curriculum for REMEDi4ALL, deciding what everyone needs to know, when they need to know it and how we teach them.
We are also continuing to champion and support the patient centricity of the project, developing what we hope will be a gold standard patient engagement plan, in true co-partnership with patients and patient groups, that can be used in all drug repurposing project both within the REMEDi4ALL lifespan and beyond!
